Excision BioTherapeutics Licenses New CRISPR Systems from UC BerkeleyGenetic Engineering & Biotechnology News (press release)Excision BioTherapeutics has become the first company to exclusively license new CRISPR systems discovered last year by Jennife… Continue reading
SnapGene and Synbio Technologies Partner to Streamline Construct Design and SynthesisBusiness Wire (press release)GSL Biotech developed SnapGene to aid the visualization, design, and documentation of DNA cloning, Gibson assembly, mutagenesis, and a gro… Continue reading
FierceBiotechCRISPR, Bayer JV tap CureVac for Cas9 mRNA constructsFierceBiotechCRISPR Therapeutics and its joint venture with Bayer have struck a deal with CureVac. The pact tasks CureVac with developing Cas9 mRNA constructs for use by CRISPR and joint… Continue reading
FierceBiotechNovartis, already up on CRISPR, CAR-T, looks to new gene editing R&DFierceBiotechThis tech builds on the work Novartis is doing out of its phoenix-from-the-flames cell and gene therapy unit, which includes CAR-T and collaborative work … Continue reading
OncLiveAR-Targeted Therapy and Immunotherapy for TNBCOncLivePanelists: Adam M. Brufsky, MD, PhD, University of Pittsburgh Cancer Institute; Michael Gnant, MD, Medical University of Vienna; Joyce A. OShaughnessy, MD, Baylor University Medical Center; Ho… Continue reading
The Columbian |
Gene therapy used to create new skin for sick boy
The Columbian Doctors treating a critically ill boy with a devastating skin disease used experimental gene therapy to create an entirely new skin for him. Two years ago, the boy was admitted to a German hospital, with blisters all over his body. In an experiment … Boy with rare disease gets brand new skin with gene therapy …Lockport Union-Sun & Journal New Gene Therapy Breakthrough in Rejuvenation MedicineSanvada Tech News (blog) New gene therapy technique saves boy’s life by growing new skinGears Of Biz BioNews –Business Recorder (press release) (blog) all 12 news articles » |
|
International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson’s Disease Clinical Trial
Nasdaq 13, 2017 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the positive six months interim … |